Janney analyst Esther Hong raised the fair value target on Cara Therapeutics (NASDAQ: CARA) to $33.00 (from $27.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Cara Therapeutics (CARA) PT Raised to $33 at JefferiesMay 29, 2019 11:20 AM Cara Therapeutics (CARA) PT Raised to $28 at H.C. WainwrightMay 29, 2019 10:55 AM Cara Therapeutics (CARA) PT Raised to $33 at StifelMay 29, 2019 10:53 AM Cara Therapeutics (CARA) PT Raised to $35 at Needham & CompanyMay 29, 2019 10:30 AM Cara Therapeutics (CARA) Phase 3 Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus Met Primary EndpointMay 29, 2019 7:02 AM Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with PruritusMay 29, 2019 7:01 AM